| Literature DB >> 22991074 |
Julien Debray1, Simon Bonte, Olivier Lozach, Laurent Meijer, Martine Demeunynck.
Abstract
A small library of heterocycle-fused quinazolin-4-ones was prepared and evaluated as kinase inhibitors. The key step of the two-step process involves the environmental friendly thermolysis of N-ethoxycarbonyl-N'-(hetero) arylguanidines at 130 °C in water. The cyclization is fully regioselective. The most active molecules, 7-(2-hydroxyethylamino)- and 7-(3-hydroxypropylamino)-pyrazolo[4,3-f]quinazolin-9-ones, inhibit DYRK1A and CLK1 at submicromolar concentrations, indicating the potential interest of this new heterocycle in drug design.Entities:
Mesh:
Substances:
Year: 2012 PMID: 22991074 DOI: 10.1007/s11030-012-9397-7
Source DB: PubMed Journal: Mol Divers ISSN: 1381-1991 Impact factor: 2.943